Engility Holdings, has been awarded a $10 million task order by the Walter Reed Army Institute of Research to conduct clinical trials for vaccines to combat the mosquito-borne Chikungunya virus.
The task order was awarded under the $900 million indefinite delivery/indefinite quantity (IDIQ) medical product research and development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.
“Our company has a long history of providing innovative medical research,” said Engility CEO Lynn Dugle.
“With this contract, our Engility medical experts will work side-by-side with the researchers at the Walter Reed Institute to fight Chikungunya and protect our men and women in uniform and all of those vulnerable to this virus.”
Chikungunya, which has no vaccine, causes fever and joint pain.
According to the Centers for Disease Control and Prevention, there were 1.7 million cases in the Americas in 2015, and it entered the continental United States for the first time in July 2016.
(Learn More, courtesy of the Pan American Health Organization and YouTube)
Engility will assist the Walter Reed Army Institute of Research in gaining a better understanding of the efficacy of potential vaccines and any adverse impacts through these clinical trials.
The new 5-year contract was awarded in the third quarter and expands the company’s work in medical health and clinical trials.
Engility, a leading provider of mission-critical and highly technical services to the U.S. government, is engineered to make a difference.
Built on a five-decade commitment to our customers and our country, Engility delivers world-class performance, efficiency and value in a broad range of services, including engineering and technology life cycle support, program and business support and specialized technical consulting.
Headquartered in Chantilly, Virginia, and with offices around the world, Engility supports customers throughout the defense, intelligence, space, federal civilian and international communities, drawing on our intimate understanding of customer needs, our deep domain expertise and our highly skilled employees to develop and deliver on-target solutions.
